TrialSpark is an American clinical trials company based in New York.
History
On November 29, 2022, TrialSpark announced the formation of Libertas Bio after it had acquired a majority position in a portfolio of immunodermatology assets from Asana BioSciences.[1]
Investors
Investors in TrialSpark include:[2][3][4][5]
- Anne Wojcicki
- ArrowMark Partners
- Casdin Capital
- Dragoneer Investment Group
- Felicis
- John Doerr
- Lachy Groom
- Sam Altman
- Section 32
- Sequoia Capital
- Sound Ventures
- Spark Capital
- Thrive Capital
- TQ Ventures
External links
TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio. (2022, November 29). BioSpace. https://web.archive.org/web/20230728172436/https://www.biospace.com/article/releases/trialspark-announces-acquisition-of-a-clinical-stage-immunodermatology-portfolio-and-formation-of-libertas-bio/ ↩︎
TrialSpark - Funding, Financials, Valuation & Investors. Crunchbase. Retrieved July 28, 2023, from https://www.crunchbase.com/organization/trialspark/company_financials ↩︎
Venture Round - TrialSpark - 2018-10-15 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 28, 2023, from https://www.crunchbase.com/funding_round/trialspark-series-unknown--abcf16de ↩︎
Series C - TrialSpark - 2021-09-30 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 28, 2023, from https://www.crunchbase.com/funding_round/trialspark-series-c--bcfe174f ↩︎
Bloomberg. (2021, September 30). Startup with $120 million for deals aims to make drugs cheaply. Mint. http://archive.today/2023.07.28-234253/https://www.livemint.com/companies/start-ups/trialspark-with-120-million-for-deals-aims-to-make-drugs-cheaply-11633008141507.html ↩︎
